Attributed to the biological complexity and poor prognosis of the disease, not all patients who are positive for acknowledged biomarkers of NSCLC (e.g., mutated EGFR, ALK, or ROS1) benefit from existing molecular therapies [21]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.